621685-55-0

Basic information

• Product Name: Pyrrolo[2,1-f][1,2,4]triazine-6-carboxaldehyde, 1,4-dihydro-5-methyl-4-oxo- (9CI)
• Synonyms: Pyrrolo[2,1-f][1,2,4]triazine-6-carboxaldehyde, 1,4-dihydro-5-methyl-4-oxo- (9CI);5-Methyl-4-oxo-1,4-dihydropyrrolo[1,2-f][1,2,4]triazine-6-carbaldehyde
• CAS NO: 621685-55-0
• Molecular Formula: C₈H₇N₃O₂
• Molecular Weight: 177.162
• Product Categories: PYRROLE
• Mol File: 621685-55-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 422.3±47.0 °C(Predicted)
• Appearance: /
• Density: 1.49±0.1 g/cm3(Predicted)
• PKA: -6.53±0.20(Predicted)
• CAS DataBase Reference: Pyrrolo[2,1-f][1,2,4]triazine-6-carboxaldehyde, 1,4-dihydro-5-methyl-4-oxo- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrrolo[2,1-f][1,2,4]triazine-6-carboxaldehyde, 1,4-dihydro-5-methyl-4-oxo- (9CI)(621685-55-0)
• EPA Substance Registry System: Pyrrolo[2,1-f][1,2,4]triazine-6-carboxaldehyde, 1,4-dihydro-5-methyl-4-oxo- (9CI)(621685-55-0)

Safety Data

• Hazardous Substances Data: 621685-55-0(Hazardous Substances Data)

Upstream product

• 621685-54-9 C₈H₉N₃O₂ 
• 427878-70-4 ethyl 4-hydroxy-5-methylpyrrolo[2,1-f ][1,2,4]-triazine-6-carboxylate 
• 427878-70-4 ethyl 5-methyl-4-oxo-3,4-dihydro-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylate 
• 621685-54-9 C₈H₉N₃O₂ 

Downstream Products

• 623152-50-1 C₂₄H₂₁N₅O₄ 
• 623152-49-8 C₃₂H₂₉FN₆O₃ 
• 621685-42-5 C₂₄H₂₃N₅O₃ 
• 621685-41-4 C₂₅H₂₅N₅O₃ 
• 621685-48-1 C₂₄H₂₃N₅O₂ 
• 621685-51-6 C₂₄H₂₃N₅O₃ 
• 621685-40-3 C₂₄H₂₃N₅O₃ 
• 621685-50-5 C₂₄H₂₃N₅O₃ 
• 621685-52-7 C₂₃H₂₀FN₅O₂ 
• 621685-49-2 C₂₃H₂₀FN₅O₂ 
• 621685-53-8 C₂₄H₂₁N₅O₄ 
• 621685-47-0 C₂₃H₂₂N₆O₂ 
• 623152-51-2 C₃₂H₂₉FN₆O₃ 
• 621685-56-1 C₁₄H₁₁N₃O₂ 

Relevant articles and documents

Commercial synthesis of a pyrrolotriazine-fluoroindole intermediate to brivanib alaninate: Process development directed toward impurity control

The development of a practical, commercial process for the preparation of 4-fluoro-2-methyl-indol-5-ol and its subsequent coupling with a pyrrolotriazine to form an advanced intermediate of the oncology therapy brivanib alaninate is described. A key aspect is the multikilogram-scale preparation of the fluoroindole intermediate from trifluoronitrobenzene and the subsequent coupling while achieving impurity minimalization. As brivanib alaninate is a high-dose drug, the synthesis of highquality API with low levels of impurities is critical.

PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS

-